Investigating how DNA damage affects immune responses in Ewing sarcoma
DNA Damage and Immunogenicity in Ewing Sarcoma
This study is looking at how damage to DNA in Ewing sarcoma cells can trigger the immune system, with the hope of finding new ways to treat this childhood cancer, especially for kids whose cancer comes back.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-11045047 on NIH RePORTER |
What this research studies
This research focuses on understanding the relationship between DNA damage and the immune response in Ewing sarcoma, a type of childhood cancer. The project aims to explore how DNA damage can activate immune pathways in tumor cells, which may lead to new treatment strategies. The research will involve laboratory experiments using cell cultures, animal models, and analyses of human specimens to gather comprehensive data. By enhancing knowledge in tumor immunology and bioinformatics, the research seeks to develop innovative approaches to combat relapsed Ewing sarcoma, which currently has a poor prognosis.
Who could benefit from this research
Good fit: Ideal candidates for this research are children and adolescents diagnosed with Ewing sarcoma, particularly those with relapsed cases.
Not a fit: Patients with other types of cancer or those whose Ewing sarcoma is not relapsed may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new immune-based therapies that improve outcomes for children with Ewing sarcoma.
How similar studies have performed: Other research has shown promise in using immune-based therapies for pediatric cancers, indicating potential success for this approach.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Bailey, Kelly — University of Pittsburgh at Pittsburgh
- Study coordinator: Bailey, Kelly
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.